Tornado Therapeutics
Biopharmaceutical company focused on discovery and development of next-generation small-molecule mTOR inhibitors (rapalog analogues) with improved selectivity profiles intended to treat aging-related conditions and other indications. Pipeline includes multiple in‑licensed small molecules progressing through lead optimization, IND‑enabling studies and preclinical efficacy testing. Organizational capabilities include medicinal chemistry, API/CMC development and partnerships/licensing.
Industries
Nr. of Employees
small (1-50)
Products
Small‑molecule mTOR inhibitor — IND‑enabling program (aging/immune/respiratory indications)
A program of orally bioavailable small‑molecule mTOR inhibitors progressing through IND‑enabling studies for indications including viral respiratory infections and oncology.
Small‑molecule mTOR inhibitor — preclinical candidate (oncology, autoimmune, dermatology)
Preclinical and lead‑stage small‑molecule candidates optimized for either TORC1 selectivity or combined TORC1/TORC2 potency across oncology, autoimmune and dermatology indications.
TOR-101
An investigational selective mTOR inhibitor therapeutic developed for viral respiratory tract infections and oncology.
TOR-103
An investigational selective mTOR inhibitor therapeutic candidate targeting viral respiratory tract infections and oncology.
TOR-105
An investigational selective mTOR inhibitor therapeutic in lead optimization for dermatology indications.
TOR-104
An investigational selective mTOR inhibitor therapeutic in lead optimization for autoimmune disease.
Small‑molecule mTOR inhibitor — IND‑enabling program (aging/immune/respiratory indications)
A program of orally bioavailable small‑molecule mTOR inhibitors progressing through IND‑enabling studies for indications including viral respiratory infections and oncology.
Small‑molecule mTOR inhibitor — preclinical candidate (oncology, autoimmune, dermatology)
Preclinical and lead‑stage small‑molecule candidates optimized for either TORC1 selectivity or combined TORC1/TORC2 potency across oncology, autoimmune and dermatology indications.
TOR-101
An investigational selective mTOR inhibitor therapeutic developed for viral respiratory tract infections and oncology.
TOR-103
An investigational selective mTOR inhibitor therapeutic candidate targeting viral respiratory tract infections and oncology.
TOR-105
An investigational selective mTOR inhibitor therapeutic in lead optimization for dermatology indications.
TOR-104
An investigational selective mTOR inhibitor therapeutic in lead optimization for autoimmune disease.
Services
Negotiation and development of in‑licensing agreements and collaborative R&D arrangements to advance compound portfolios.
Negotiation and development of in‑licensing agreements and collaborative R&D arrangements to advance compound portfolios.
Expertise Areas
- Medicinal chemistry and small‑molecule discovery
- mTOR biology and translational geroscience
- API/CMC development and scale‑up
- Preclinical candidate selection and IND‑enabling studies
Key Technologies
- Small‑molecule kinase inhibitors
- TORC1/TORC2 selectivity profiling
- Preclinical aging and immune function models
- IND‑enabling study design
News & Updates
Article referencing next‑generation rapamycin derivatives and efforts to increase human healthspan.
Review and clinical trial discussion on mTOR inhibitors to improve immune function in older adults (phase 2b/3 trials referenced).
Clinical trial results showing improved immune responses and reduced infection rates with selective TORC1 inhibition strategies.
Article referencing next‑generation rapamycin derivatives and efforts to increase human healthspan.
Review and clinical trial discussion on mTOR inhibitors to improve immune function in older adults (phase 2b/3 trials referenced).
Clinical trial results showing improved immune responses and reduced infection rates with selective TORC1 inhibition strategies.